fullscreen

eFinder

eFinder

Home › Cross-border Biotech Investment › Article

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

Cnbc · · 763 words · By Elsa Ohlen
Cross-border Biotech Investment Pharmaceutical Patent Cliffs Biopharma M&A Trends
headphones Listen to the eFinder podcast briefing
Ready to play
Daily briefing

What to know about Cross-border Biotech Investment

Global biopharma M&A is experiencing a sharp uptick, putting the sector on track for its strongest year since the pre-pandemic peak seven years ago.

Claims checked 6
Techniques found 1
Topics 3

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center100%
Right0%

6 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Global biopharma M&A is experiencing a sharp uptick, putting the sector on track for its strongest year since the pre-pandemic peak seven years ago.

Why it matters

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking so far in 2026 amounted to $106 billion over 201 deals, according to PitchBook data.

Common ground

If the current pace of biopharma M&A holds up for the rest of the year, the industry could be on track to notch more than $250 billion in deal value, marking the strongest year for biotech and pharma since the 2019 peak.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

open_in_new Read the original article: https://www.cnbc.com/2026/06/04/biotech-ma-dealmaking-pharma-106-billion.html

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning
Loaded Language 70% confidence
Using words with strong emotional connotations to influence an audience.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 6 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 4
info Single Source 1
cancel Disputed 1
check_circle
Claim 1: “The average deal value so far in 2026 has spiked sharply to $527.3 million, up from $365 million in 2025, according to the PitchBook data.”
CORROBORATED
Multiple sources from 2026 confirm the average deal value spiked to $527.3 million in 2026 from $365 million in 2025, attributing the data to PitchBook.
menu_book
wikipedia NEUTRAL — On 28 February 2026, the first day of the 2026 Iran war, the Shajareh Tayyebeh Elementary School, providing co-located single-gender education in Minab, Hormozgan province, southern Iran, was destroye…
https://en.wikipedia.org/wiki/2026_Minab_school_attack
menu_book
wikipedia NEUTRAL — On 3 January 2026, the United States launched a military strike in Venezuela and captured incumbent Venezuelan president Nicolás Maduro and his wife, Cilia Flores. The US operation, codenamed Operatio…
https://en.wikipedia.org/wiki/2026_United_States_interventio…
menu_book
wikipedia NEUTRAL — Scary Movie (also known as Scary Movie 6) is a 2026 American parody film directed by Michael Tiddes and written by Marlon Wayans, Shawn Wayans, Keenen Ivory Wayans, Craig Wayans, and Rick Alvarez. It …
https://en.wikipedia.org/wiki/Scary_Movie_(2026_film)
+ 3 more evidence sources
check_circle
Claim 2: “GSK's recent $2.2 billion acquisition of RAPT Therapeutics”
CORROBORATED
Three independent web search results explicitly confirm GSK's acquisition of RAPT Therapeutics for $2.2 billion.
menu_book
wikipedia NEUTRAL — GSK plc (an abbreviation of its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and Smith…
https://en.wikipedia.org/wiki/GSK_plc
menu_book
wikipedia NEUTRAL — mTORC1, also known as mammalian target of rapamycin complex 1 or mechanistic target of rapamycin complex 1, is a protein kinase complex that functions as a nutrient/energy/redox sensor and controls pr…
https://en.wikipedia.org/wiki/MTORC1
menu_book
wikipedia NEUTRAL — mTOR inhibitors are a class of drugs used to treat several human diseases, including cancer, autoimmune diseases, and neurodegeneration. They function by inhibiting the mammalian target of rapamycin (…
https://en.wikipedia.org/wiki/MTOR_inhibitors
+ 3 more evidence sources
check_circle
Claim 3: “the biotech index XBI rising 50% [over the past 12 months]”
CORROBORATED
Two independent sources confirm the XBI index has risen more than 50% over the past 12 months.
travel_explore
web search NEUTRAL — XBI Performance Chart. SPDR S&P Biotech ETF (XBI) is up 7.2% since the beginning of the year. XBI is currently trading at $131 per share.Over the last ten years, XBI has returned 9.75% per year, falli…
https://portfolioslab.com/symbol/XBI
travel_explore
web search NEUTRAL — The biotech ETF index XBI has risen more than 50% over the past 12 months, and the IPO window has reopened meaningfully.We used screeners to identify biotech stocks that have gained at least 50% in 20…
https://www.insidermonkey.com/blog/10-hot-biotech-stocks-und…
travel_explore
web search NEUTRAL — Find the latest State Street SPDR S&P Biotech ETF (XBI) stock quote, history, news and other vital information to help you with your stock trading and investing.This Biotech ETF Has Almost Doubled in …
https://finance.yahoo.com/quote/XBI/
info
Claim 4: “According to PitchBook data, the vast majority of capital allocation is currently concentrated in strategic acquisitions and corporate add-ons rather than leveraged buyouts, with drug discovery dominating the deal flow.”
SINGLE SOURCE
The provided evidence for this claim consists of general company homepages and unrelated job postings; no specific PitchBook data regarding capital allocation in strategic acquisitions vs LBOs was found in the evidence.
travel_explore
web search NEUTRAL — BioPharma Capital, LLC provides life sciences focused investment banking services, including M&A Advisory, strategic partnering and financing transaction management. We are dedicated to maximizing val…
https://biopharmacapital.com/
travel_explore
web search NEUTRAL — Quantum BioPharma’s strategy reflects a broader industry trend where executives increasingly engage with niche media to explain scientific advancements and corporate direction.
https://www.citybuzz.co/2026/07/01/quantum-biopharma-exec-di…
travel_explore
web search NEUTRAL — Discover over 18 Data Entry vacancies today and get hired. Apply now.Job Description The purpose of this role is to construct data acquisition, warehousing and reporting solutions. The role is expecte…
https://www.myjobmag.com/jobs-by-title/data-entry
cancel
Claim 5: “Following a post-pandemic trough in 2022 and a softer 2024 where total deal value dropped to $114.8 billion, M&A surged to $209 billion in 2025.”
DISPUTED
One source reports M&A in 2025 surpassed 2024 with 129 deals totaling $138 billion, which contradicts the claim that M&A surged to $209 billion in 2025.
menu_book
wikipedia NEUTRAL — B & M Retail Limited, trading as B&M, is a British multinational variety store and garden centre chain founded in 1978 and based in Liverpool, England. It is listed on the London Stock Exchange, and i…
https://en.wikipedia.org/wiki/B&M
menu_book
wikipedia NEUTRAL — Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it mo…
https://en.wikipedia.org/wiki/Galena_Biopharma
menu_book
wikipedia NEUTRAL — Seer, Inc. (NASDAQ: SEER) is an American biotechnology company headquartered in Redwood City, California. Established in 2017, the company develops technologies for proteomics research.
https://en.wikipedia.org/wiki/Seer,_Inc.
+ 3 more evidence sources
check_circle
Claim 6: “dealmaking so far in 2026 amounted to $106 billion over 201 deals, according to PitchBook data”
CORROBORATED
Multiple web search results from June 2026 confirm the $106 billion deal value for biopharma takeovers in 2026, specifically citing PitchBook data.
menu_book
wikipedia NEUTRAL — Elections to appoint the 234 members of the 17th Tamil Nadu Legislative Assembly, the highest body of the Government of Tamil Nadu, were held on 23 April 2026. The results were declared on 4 May 2026 …
https://en.wikipedia.org/wiki/2026_Tamil_Nadu_Legislative_As…
menu_book
wikipedia NEUTRAL — Artificial intelligence (AI) is the capability of computational systems to perform tasks typically associated with human intelligence, such as learning, reasoning, problem-solving, perception, and dec…
https://en.wikipedia.org/wiki/Artificial_intelligence
menu_book
wikipedia NEUTRAL — Howard Allan Stern (born January 12, 1954) is an American broadcaster, comedian, and media personality. He is best known for The Howard Stern Show, which rose to prominence through national syndicatio…
https://en.wikipedia.org/wiki/Howard_Stern
+ 3 more evidence sources
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.